An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
DermTech has joined the Pediatric Dermatology Research Alliance (PeDRA) Corporate Council to contribute to pediatric skin disease research. This partnership aims to improve treatment options for children with skin disorders, enhancing DermTech's focus on precision dermatology through its non-invasive genomics platform. DermTech Stratum™ will aid in developing research initiatives and guidelines in pediatric dermatology. The company will participate in upcoming PeDRA events, further solidifying its role in advancing dermatological health for children.
Positive
Membership in PeDRA enhances research and collaboration opportunities.
DermTech's Stratum™ is positioned to advance pediatric dermatology.
Participation in significant upcoming industry events fosters networking and knowledge sharing.
Negative
None.
LA JOLLA, Calif.--(BUSINESS WIRE)--
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its membership in the Corporate Council of the Pediatric Dermatology Research Alliance (PeDRA). PeDRA is a nonprofit research network with the mission to create, inspire and sustain research to prevent, treat and cure childhood skin disease by bringing together pediatric dermatologists for organized studies and collaborative initiatives. With more than 600 members, PeDRA is accelerating research and advancing development of new treatments for children living with dermatologic diseases.
As a member of the PeDRA Corporate Council, DermTech will contribute to the development and expansion of PeDRA’s research infrastructure and serve as a valuable partner to PeDRA members. This aligns with the capabilities of DermTech Stratum™, a translational medicine service offering that enables non-invasive approaches to precision and personalized dermatology using biomarker platform technology and subsequent analysis.
"We are proud to join the PeDRA Corporate Council to help progress research and treatment options for children impacted by life-altering skin diseases,” said Michael Howell, Ph.D., chief scientific officer at DermTech. “By leveraging precision dermatology, we are providing a non-invasive way to improve how a variety of skin diseases are diagnosed and treated. We look forward to working with the PeDRA team and other like-minded Corporate Council members to advance this mission.”
DermTech’s membership comes ahead of the 2022 PeDRA Corporate Council Roundtable, taking place on July 8, 2022 in Indianapolis, Ind. Titled “PeDRA’s Role in Consensus Guidelines and Best Practice Recommendations,” the event will focus on the development of guidelines and recommendations in pediatric dermatology. DermTech will also attend the 10th PeDRA Annual Conference, taking place from November 3 – 5, 2022 in Bethesda, Md., which is expected to bring more than 350 scientists, industry partners, patients and advocates together.
DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics platform. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using its Smart Stickers™. DermTech markets and develops products that facilitate the early detection of skin cancers and is developing products that assess inflammatory diseases and customize drug treatments. For additional information, please visit DermTech.
Forward-Looking Statements:
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations with respect to: the performance, patient benefits, benefits to research partners and collaborators, cost-effectiveness, commercialization and adoption of DermTech’s products and services and the market opportunity therefor, and DermTech’s ability to expand its product and service offerings. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products and services; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by Medicare and private payors; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in (x) the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and (y) other documents filed or to be filed by DermTech with the SEC. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward-looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
What is DermTech's recent announcement regarding PeDRA?
DermTech announced its membership in the Pediatric Dermatology Research Alliance (PeDRA) Corporate Council to enhance pediatric skin disease research.
How does DermTech contribute to pediatric dermatology?
Through its membership in PeDRA, DermTech will leverage its precision dermatology capabilities to improve treatment options for children with skin diseases.
What events will DermTech participate in related to PeDRA?
DermTech will attend the PeDRA Corporate Council Roundtable on July 8, 2022, and the 10th PeDRA Annual Conference from November 3-5, 2022.
What is DermTech Stratum™?
DermTech Stratum™ is a translational medicine service that utilizes non-invasive methods to enable precision dermatology using biomarker technology.
